Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Cell Reports. Medicine|December 9, 2020
Pre-existing Hemagglutinin Stalk Antibodies Correlate with Protection of Lower Respiratory Symptoms in Flu-Infected Transplant PatientsTeresa Aydillo, Alba Escalera, Shirin Strohmeier, et al.
Nature Communications|December 21, 2022
Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation siteDaniel Stadlbauer, Meagan McMahon, Hannah L Turner, et al.
Science (New York, N.Y.)|October 29, 2020
Robust neutralizing antibodies to SARS-CoV-2 infection persist for monthsAnia Wajnberg, Fatima Amanat, Adolfo Firpo, et al.
Scientific Reports|June 2, 2022
Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvantsJenny E Hernandez-Davies, Emmanuel P Dollinger, Egest J Pone, et al.
NPJ Vaccines|August 30, 2022
The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccinationJohannes B Goll, Aarti Jain, Travis L Jensen, et al.
Immunity|September 25, 2020
Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly ProtectiveAnders Madsen, Ya-Nan Dai, Meagan McMahon, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2022
Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza virusesMeagan McMahon, George O'Dell, Jessica Tan, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 17, 2021
Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopesAlec W Freyn, Julianna Han, Jenna J Guthmiller, et al.
Biorxiv : the Preprint Server for Biology|October 27, 2020
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein VaccineSonia Jangra, Jana De Vrieze, Angela Choi, et al.
Medrxiv : the Preprint Server for Health Sciences|May 25, 2021
Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccinesNicolás A Muena, Tamara García-Salum, Catalina Pardo-Roa, et al.
Pageof 7